Potential solutions for pricing and reimbursement of high-cost combination products

Pricing and reimbursement solutions for high-cost combination therapies

The scale and potential impact of high-cost combinations coming to market in the next 2–3 years will force a significant change in pricing and reimbursement policies.

European advisors met with PRMA Consulting to provide unique, targeted market access insights into the challenges of pricing combination therapies, and to discuss effective strategies for market access success.

This market access paper explores:

  • the challenges for pricing and market access associated with high-cost combination therapies
  • three potential market access strategies for demonstrating value for combination therapies.

FREE EBOOK

Free download

Latest insights

The evolution of the PRMA Healthcheck®

ICER 2020 value assessment framework: 7 updates that market ...

How collaboration and connectivity can accelerate payer ...